Cytochrome P450 mediates dopamine formation in the brain in vivo

Journal of Neurochemistry

Volumn 118, Issue 5, 2011, Pages 806-815

  Bromek, Ewa ^a   Haduch, Anna ^a   Gołembiowska, Krystyna ^a   Daniel, Władysława A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

CYP2D forms; cytochrome P450; dopamine; in vivo microdialysis; rat brain structures; tyramine hydroxylation

Indexed keywords

CYTOCHROME P450; DOPAMINE; METIROSINE; PARGYLINE; QUININE; RESERPINE; TYRAMINE;

ANATOMICAL VARIATION; ANIMAL EXPERIMENT; ARTICLE; BRAIN FUNCTION; CATALYSIS; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE METABOLISM; DRUG INHIBITION; FRONTAL CORTEX; HYDROXYLATION; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PRIORITY JOURNAL; RAT; SUBSTANTIA NIGRA;

ADRENERGIC UPTAKE INHIBITORS; ALPHA-METHYLTYROSINE; ANALGESICS, NON-NARCOTIC; ANIMALS; BRAIN; CYTOCHROME P-450 ENZYME SYSTEM; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INHIBITORS; MALE; MICRODIALYSIS; MODELS, STATISTICAL; QUININE; RATS; RATS, WISTAR; RESERPINE; TYRAMINE;

RATTUS;

EID: 80051784500     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2011.07339.x     Document Type: Article

References (75)

1. Akhmedova S. N., Pushinova E. A., Yakimovsky A. F., Avtonomov V. V., and, Schwarz E. I., (1995) Frequency of a specific cytochrome P4502D6B (CYP2D6B) mutant allele in clinically differentiated groups of patients with Parkinson disease. Biochem. Mol. Med. 54, 88-90.
2. Alves G., Kurz M., and, Larsen J. P., (2004) Cigarette smoking in Parkinson's disease: influence on disease progression. Mov. Disord. 19, 1087-1092. (Pubitemid 39302846)
3. Atkinson A., Singleton A. B., Steward A., Ince P. G., Ferry R. H., McKeith I. G., Fairbairn A. F., Edwardson J. A., Daly A. K., and, Morris C. M., (1999) CYP2D6 is associated with Parkinson's disease but not with dementis with Lewy Bodies or Alzheimer's disease. Pharmacogenetics 9, 31-35. (Pubitemid 29176721)
4. Baum L. O., and, Strobel H. W., (1997) Regulation of expression of cytochrome P-450 2D mRNA in rat brain with steroid hormones. Brain Res. 765, 67-73. (Pubitemid 27374915)
5. Bertilsson L., Alm C., De Las Carreras C., Widen J., Edman G., and, Schalling D., (1989) Debrisoquine hydroxylation polymorphism and personality. Lancet 1, 555. (Pubitemid 19075230)
6. Bertler A., and, Rosengren E., (1959) Occurrence and distribution of catechol amines in brain. Acta Physiol. Scand. 47, 350-361.
7. Betarbet R., Turner R., Chockkan V., DeLong M. R., Allers K. A., Walters J., Levey A. I., and, Greenamyre J. T., (1997) Dopaminergic neurons intrinsic to the primate striatum. J. Neurosci. 17, 6761-6768. (Pubitemid 27366627)
8. Boulton A. A., (1976) Identification, distribution, metabolism, and function of meta and para tyramine, phenylethylamine and tryptamine in brain. Adv. Biochem. Psychopharmacol. 15, 57-67.
9. Boulton A. A., Juorio A. V., Philips S. R., and, Wu P. H., (1977) The effects of reserpine and 6-hydroxydopamine on the concentrations of some arylakylamines in rat brain. Br. J. Pharmacol. 59, 209-214. (Pubitemid 8015161)
10. Bromek E., Haduch A., and, Daniel W. A., (2010) The ability of cytochrome P450 2D forms to synthesize dopamine in the brain: an in vitro study. Eur. J. Pharmacol. 626, 171-178.
11. Chinta S. J., Pal H. V., Upadhya S. C., Boyd M. R., and, Ravindranath V., (2002) Constitutive expression and localization of the major drug metabolizing enzyme, cytochrome P4502D in human brain. Brain Res. Mol. Brain Res. 103, 49-61. (Pubitemid 34775033)
12. Dahlström A., and, Fuxe K., (1965) Evidence for the existence of monoamine neurons in the central nervous system. Acta Physiol. Scand. 64 (Suppl. 247), 1-85.
13. Daniel W. A., (2003) Mechanisms of cellular distribution of psychotropic drugs. Significance of drug action and interactions. Prog. Neuropsychopharmacol. Biol. Psychiatry 27, 65-73. (Pubitemid 36126648)
14. Daniel W. A., Wõjcikowski J., and, Pałucha A., (2001) Distribution of psychotropic drugs in the grey and white matter of the brain. In vitro studies. Br. J. Pharmacol. 134, 807-814. (Pubitemid 33016152)
15. Di Chiara G., and, Imperato A., (1988) Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc. Natl Acad. Sci. USA 85, 5274-5278.
16. Dorado P., Peñas-Lledo E. M., and, Llerena A., (2007) CYP2D6 polymorphism: implications for antipsychotic drug response, schizophrenia and personality traits. Pharmacogenomics 8, 1597-1608. (Pubitemid 350286402)
17. Dutheil F., Beaune P., and, Loriot M.-A., (2008) Xenobiotic metabolizing enzymes in the central nervous system: contribution of cytochrome P450 enzymes in normal and pathological human brain. Biochimie 90, 426-436.
18. Dutheil F., Dauchy S., Diry M., et al. (2009) Xenobiotic-metabolizing enzymes and transporters in the central in the normal human brain: regional and cellular mapping as a basis for putative roles in cerebral function. Drug Metab. Dispos. 37, 1528-1538.
19. Dyck L. E., (1989) Release of some endogenous trace amines from rat striatal slices in the presence and absence of a monoamine oxidase inhibitor. Life Sci. 44, 1149-1156. (Pubitemid 19152004)
20. Dymecki J., Lechowicz W., Bertrand E., and, Szpak G. M., (1996) Changes in dopaminergic neurons of the mesocorticolimbic system in Parkinson's disease. Folia Neuropathol. 43, 102-106. (Pubitemid 126504543)
21. Ehringer H., and, Hornykiewicz O., (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin. Wochenschrift 38, 1236-1239.
22. Eisenhofer G., Aneman A., Friberg P., Hooper D., FÃ¥ndriks L., Lonroth H., Hunyady B., and, Mezey E., (1997) Substantial production of dopamine in the human gastrointestinal tract. J. Clin. Endocrinol. Metab. 82, 3864-3871. (Pubitemid 27509384)
23. Everitt B. J., and, Robbins T. W., (2005) Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat. Neurosci. 8, 1481-1489. (Pubitemid 41573659)
24. Ferrari R., Le Novère N., Picciotto M. R., Changeux J. P., and, Zoll M., (2001) Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur. J. Neurosci. 15, 1810-1818. (Pubitemid 35471906)
25. Fratiglioni L., and, Wang H. X., (2000) Smoking and Parkinson's and Alzheimer's disease: review of the epidemiological studies. Behav. Brain Res. 113, 117-120. (Pubitemid 30645549)
26. Funae Y., Kishimoto W., Cho T., Niwa T., and, Hiroi T., (2003) CYP2D in the brain. Drug Metab. Pharmacokin. 18, 337-349.
27. Gołembiowska K., Dziubina A., Kowalska M., and, Kamińska K., (2008) Paradoxical effects of adenosine receptor ligands on hydroxyl radical generation by L-DOPA in the rat striatum. Pharmacol. Rep. 60, 319-330.
28. González I., Peñas-Lledo E. M., Pérez B., Dorado P., Alvarez M., and, Llerena A., (2008) Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 9, 833-840.
29. Haduch A., Bromek E., and, Daniel W. A., (2011) The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain. Eur. J. Pharmacol. 651, 51-58.
30. Hedlund E., Wyss A., Kainu T., Backlund M., Köhler C., Pelto-Huikko M., Gustafsson J.-Å., and, Warner M., (1996) Cytochrome P4502D4 in the Brain: specific neuronal regulation by clozapine and toluene. Mol. Pharmacol. 50, 342-350. (Pubitemid 26265139)
31. Henry J.-P., and, Scherman D., (1989) Radioligands of the vesicular monoamine transporter and their use as markers of monoamine storage vesicles. Biochem. Pharmacol. 38, 2395-2404. (Pubitemid 19188401)
32. Hiroi T., Imaoka S., and, Funae Y., (1998) Dopamine formation from tyramine by CYP2D6. Biochem. Biophys. Res. Commun. 249, 838-843. (Pubitemid 28441925)
33. Hornykiewicz O., and, Kish S. J., (1986) Biochemical pathophysiology of Parkinson's disease. Adv. Neurol. 45, 19-34.
34. 11C]-tetrabenazine and positron emission tomography. J. Neurochem. 60, 2315-2318. (Pubitemid 23148808)
35. Kirchheiner J., Seeringer A., Godoy A., Ohmle B., Maier C., Beschoner P., Sim E.-J., and, Viviani R., (2011) CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol. Psychiat. 16, 333-341.
36. Kobayashi S., Murray S., Watson D., Sesardic D., Davies D. S., and, Boobis A. R., (1989) The specificity of inhibition of debrisoquine 4-hydroxylase activity by quinidine and quinine in the rat is the inverse of that in man. Biochem. Pharmacol. 38, 2795-2799. (Pubitemid 19219839)
37. Kuczenski R. T., and, Mandell A. J., (1972) Regulatory properties of soluble and particulate rat brain tyrosine hydroxylase. J. Biol. Chem. 247, 3114-3122.
38. Kurth M. C., and, Kurth J. H., (1993) Variant cytochrome P450 CYP2D6 allelic frequencies in Parkinson's disease. Am. J. Mol. Genet. 48, 166-168. (Pubitemid 23292013)
39. Laverty R., and, Sharman D. F., (1965) The estimation of small quantities of 3,4-dihyroxyphenylethylamine in tissues. Br. J. Pharmacol. 24, 538-548.
40. Llerena A., Edman G., Cobaleda J., Benitez J., Schalling D., and, Bertilsson L., (1993) Relationship between personality and debrisoquine hydroxylation capacity. Suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6. Acta Psychiatr. Scand. 87, 23-28. (Pubitemid 23024862)
41. Mann A., and, Tyndale R. F., (2010) Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells. Eur. J. Neurosci. 31, 1185-1193.
42. Mann A., Miksys S., Lee A., Mash D. C., and, Tyndale R. F., (2008) Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology 55, 1147-1155.
43. McCann S. J., Fond S. M., James K. M., and, Le Couter D. G., (1997) The association between polymorphisms in the cytochrome P-450 2D6 gene and Parkinson's disease: a case-control study and meta-analysis. J. Neurol. Sci. 153, 50-53. (Pubitemid 28010066)
44. Miksys S. L., and, Tyndale R. F., (2002) Drug-metabolizing cytochrome P450s in the brain. J. Psychiatry Neurosci. 27, 406-415. (Pubitemid 36110781)
45. Miksys S., and, Tyndale R. F., (2004) The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metab. Rev. 36, 313-333. (Pubitemid 38802491)
46. Miksys S., Rao Y., Sellers E. M., Kwan M., Mendis D., and, Tyndale R. F., (2000) Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica 30, 547-564. (Pubitemid 30449566)
47. Miksys S., Rao Y., Hoffmann E., Mash D. C., and, Tyndale R. F., (2002) Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J. Neurochem. 82, 1376-1387.
48. Oldendorf W. H., (1971) Brain uptake of radiolabelled amino acids, amines and hexoses after arterial injection. Am. J. Physiol. 221, 1629-1639.
49. Ossowska K., Śmiałowska M., Kuter K., et al. (2006) Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats: implications for Parkinson's disease. Neuroscience 141, 2155-2165. (Pubitemid 44233146)
50. Porritt M. J., Batchelor P. E., Hughes A. J., Kalnins R., Donnan G. A., and, Howells D. W., (2000) New dopaminergic neurons in Parkinson's disease striatum. Lancet 356, 44-45. (Pubitemid 30416998)
51. Pussard E., Merzouk M., and, Barennes H., (2007) Increased uptake of quinine into the brain by inhibition of P-glycoprotein. Eur. J. Pharm. Sci. 32, 123-127. (Pubitemid 47299300)
52. Quik M., Parameswaran N., McCallum S. E., Bordia T., Bao S., McCormack A., Kim A., Tyndale R. F., Langston J. W., and, Di Monte D. A., (2006) Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. J. Neurochem. 98, 1866-1875. (Pubitemid 44313641)
53. Riedl A. G., Watts P. M., Edwards R. J., Schulz-Utermoehl T., Boobis A. R., Jenner P., and, Marsden C. D., (1999) Expression and localization of CYP2D enzymes in rat basal ganglia. Brain Res. 822, 175-191. (Pubitemid 29222841)
54. Sardar A., Juorio A. V., and, Boulton A. A., (1987) The concentration of p- and m-tyramine in the rat mesolimbic system: its regional distribution and effect of monoamine oxidase inhibition. Brain Res. 412, 370-374. (Pubitemid 17091182)
55. Scatton B., Javoy-Agid F., Rouquier L., Dubois B., and, Agid Y., (1983) Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res. 275, 321-328. (Pubitemid 13004530)
56. Schümann H. J., (1956) Determination of hyroxytyramine (dopamine) in symphatetic nerves and ganglia. Naunyn Schmiedebergs Arch. Exp. Pathol. Pharmakol. 227, 566-573.
57. Silkaitis R. P., and, Mosnaim A. D., (1976) Pathways linking L-phenylalanine and 2-phenylethylamine with p-tyramine in rabbit brain. Brain Res. 114, 105-115.
58. Singh S., Singh K., Patel D. K., Singh C., Nath C., Singh V. K., Singh R. K., and, Singh M. P., (2009) The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6- tetrahydropyridine-induced Parkinson's disease phenotype and nicotine-mediated neuroprotection. Rejuvenation Res. 12, 185-197.
59. Siow Y. L., and, Dakshinamurti K., (1985) Effect of pyridoxine deficiency on aromatic L-amino acid decarboxylase in adult rat brain. Exp. Brain Res. 59, 575-581. (Pubitemid 15042257)
60. Stefanović M., Topić E., Ivanisević A. M., Relja M., and, Korsić M., (2000) Genotyping of CYP2D6 in Parkinson's disease. Clin. Chem. Lab. Med. 38, 929-934.
61. Steiner E., Dumond E., Spina E., and, Dahlqvist R., (1988) Inhibition of desipramine 2-hydroxylation by quinidine and quinine. Clin. Pharmacol. Ther. 43, 577-581.
62. Tomkins D. M., Otton S. V., Joharchi N., Li N.-Y., Balster R. F., Tyndale R. F., and, Sellers E. M., (1997) Effects of Cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. J. Pharmacol. Exp. Ther. 280, 1374-1382. (Pubitemid 27166736)
63. Touze J.-E., Heno P., Fourcade L., Deharo J.-C., Thomas G., Bohan S., Paule P., Riviere P., Kouassi E., and, Buguet A., (2002) The effect of antimalarial drugs on ventricular repolarization. Am. J. Trop. Med. Hyg. 67, 54-60. (Pubitemid 35034320)
64. Tsuneoka Y., Matsuo Y., Iwahashi K., Takeuchi H., and, Ichikawa Y., (1993) A novel cytochrome P-450IID6 mutant gene associated with Parkinson's disease. J. Biochem. 114, 263-266. (Pubitemid 23254384)
65. Tyndale R. F., Li Y., Li N.-Y., Messina E., Miksys S., and, Sellers E. M., (1999) Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metab. Dispos. 27, 924-930. (Pubitemid 29347593)
66. Verbeek M. M., Geurtz P. B. H., Willemsen M. A. A. P., and, Wevers R. A., (2007) Aromatic L-amino acid decarboxylase enzyme activity in deficient patients and heterozygotes. Mol. Genet. Metab. 90, 363-369. (Pubitemid 46505283)
67. Volkow N. D., Fowler J. S., Wang G.-J., and, Swanson J. M., (2004) Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol. Psychiatry 9, 557-569. (Pubitemid 38850435)
68. Warner M., and, Gustafsson J.-Å., (1994) Effect of ethanol on cytochrome P450 in the rat brain. Proc. Natl Acad. Sci. USA 91, 1019-1023. (Pubitemid 24048500)
69. Wassenberg T., Willemsen M. A. A. P., Geurtz P. B. H., Lammens M., Verrijp K., Wilmer M., Lee W. T., Wevers R. A., and, Verbeek M. M., (2010) Urinary dopamine in aromatic L-amino acid decarboxylase deficiency: the unsolved paradox. Mol. Genet. Metab. 101, 349-356.
70. Willemsen M. A., Verbeek M. M., Kamsteeg E. J., et al. (2010) Tyrosine hydroxylase deficiency: a treatable disorder of brain catecholamine biosynthesis. Brain 133, 1810-1822.
71. Wyss A., Gustafsson J.-Å., and, Warner M., (1995) Cytochromes P450 of the 2D subfamily in rat brain. Mol. Pharmacol. 47, 1148-1155.
72. Yu A.-M., Idle J. R., Byrd L. G., Krausz K. W., Küpfer A., and, Gonzalez F. J., (2003) Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13, 173-181. (Pubitemid 36324247)
73. Yue J., Miksys S., Hoffmann E., and, Tyndale R. F., (2008) Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. J. Psychiatry Neurosci. 33, 54-63. (Pubitemid 351252497)
74. Zanger U. M., Raimundo S., and, Eichelbaum M., (2004) Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch. Pharmacol. 369, 23-37. (Pubitemid 38161221)
75. Zhu M.-Y., Juorio A. V., Paterson I. A., and, Boulton A. A., (1994) Regulation of aromatic L-amino acid decarboxylase in rat striatal synaptosomes: effect of dopamine receptor agonist and antagonist. Br. J. Pharamcol. 112, 23-30. (Pubitemid 24151698)